PT628. First in class melatonin MT2 receptors agonists for neuropathic pain

نویسندگان

  • Gabriella Gobbi
  • Martha Lopez-Canul
  • Enza Palazzo
  • Sergio Dominguez-Lopez
  • Livio Luongo
  • Baptiste Lacoste
  • Stefano Comai
  • Debora Angeloni
  • Franco Fraschini
  • Gilberto Spadoni
  • Annalida Bedini
  • Giorgio Tarzia
  • Sabatino Maione
  • Vinicio Granados-Soto
چکیده

Objective: Brain-derived neurotrophic factor (BDNF) is known to be involved in the plasticity of neurons and pathophysiology of several psychiatric illnesses. The purpose of this study was to determine whether there is an abnormality of plasma BDNF concentrations in patients with somatization disorder, and the alteration after antidepressant treatment. Methods: The 27 patients with somatization disorder (mean age: 46.33 ± 9.73 years, 12 males, 15 females) who fulfilled the DSM-IV criteria for somatization disorder and 27 healthy controls (mean age: 46.81 ± 6.81 years, 12 males, 15 females) were enrolled in the study. The clinical assessment of the somatization disorder was measured by Korean version of Wahler physical symptom inventory, Beck Depression Inventory, Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale. BDNF was assayed using the DuoSet ELISA Development System (R&D Systems. DY248). The difference in the plasma BDNF levels between patients and healthy controls was analyzed using non-parametric MannWhitney test by the SPSS 15.0 (p<0.05). Moreover, we assessed the alteration of plasma BDNF concentrations after treatment using Wilcoxon Signed Ranks test. 22 among 27 patients with somatization disorder took the selective serotonin reuptake inhibitors for 9 to 16 weeks. And the correlations between the BDNF level and the clinical assessment scale scores were examined using Spearman correlation coefficient. Results: The mean plasma BDNF levels of 27 patients with somatization disorder were significantly lower compared with those of controls (83.61 ± 89.97 pg/ml vs. 771.36 ± 562.14 pg/ ml, Z=-5.735, p<0.001). In 22 patients after the antidepressant treatment, the plasma BDNF concentrations were significantly increased (118.13 ± 91.45 pg/ml vs. 72.92 ± 88.21 pg/ml, Z=-2.029, p=0.042). However, clinical assessment scales did not reveal any significant correlations with BDNF levels. Conclusions: These results suggest that BDNF may play a role in the pathophysiology of somatization disorder. Index Words: BDNF, Neurotrophin, Somatization disorder

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Melatonin and its agonists in pain modulation and its clinical application.

Melatonin, the hormone of darkness has many physiological functions in the body and also exerts a number of pharmacological effects. Most of these actions of melatonin are mediated through melatonin membrane receptors like MT1/MT2 receptors or through nuclear orphan receptors like RZR/ROR receptors or through calcium binding proteins in the cytosol. The finding that pain perception is circadian...

متن کامل

Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism.

Melatonin (MT) is a neurohormone synthesized and secreted by the pineal gland. MT plays an important role in the regulation of physiological and neuroendocrine functions. The purpose of this study was to assess the overall effect of melatonin on neuropathic pain, the type of melatonin receptor involved, and potential role of the opioid system and GABA(A) receptors. The experiments were conducte...

متن کامل

Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology.

BACKGROUND Melatonin (MLT) is a pleiotropic neurohormone controlling many physiological processes and whose dysfunction may contribute to several different diseases, such as neurodegenerative diseases, circadian and mood disorders, insomnia, type 2 diabetes and pain. Melatonin is synthesized by the pineal gland during the night and acts through 2 G-protein coupled receptors (GPCRs), MT1 (MEL1a)...

متن کامل

Design of subtype selective melatonin receptor agonists and antagonists.

Studies of the physiological actions of melatonin have been hindered by the lack of specific, potent and subtype selective agonists and antagonists. In the present study, we describe the utility of a melanophore cell line from Xenopus laevis for exploring structure-activity relationships among novel melatonin analogues and report a novel MT2-selective agonist (IIK7) and MT2-selective receptor a...

متن کامل

Melatonin Suppresses Neuropathic Pain via MT2-Dependent and -Independent Pathways in Dorsal Root Ganglia Neurons of Mice

Melatonin (Mel) and its receptors (MT1 and MT2) have a well-documented efficacy in treating different pain conditions. However, the anti-nociceptive effects of Mel and Mel receptors in neuropathic pain (NP) are poorly understood. To elucidate this process, pain behaviors were measured in a dorsal root ganglia (DRG)-friendly sciatic nerve cuffing model. We detected up-regulation of MT2 expressio...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 19  شماره 

صفحات  -

تاریخ انتشار 2016